These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29047306)

  • 1. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
    Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
    Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature.
    Boissier E; Genebrier S; Lakhal K; Nedelec-Gac F; Trossaërt M; Ternisien C; Gouin-Thibault I
    Thromb Haemost; 2018 Aug; 118(8):1488-1490. PubMed ID: 29960274
    [No Abstract]   [Full Text] [Related]  

  • 7. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
    Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
    Adelmann D; Wiegele M; Wohlgemuth RK; Koch S; Frantal S; Quehenberger P; Scharbert G; Kozek-Langenecker S; Schaden E
    Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
    Freyburger G; Macouillard G; Khennoufa K; Labrouche S; Molimard M; Sztark F
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):925-33. PubMed ID: 26258673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
    Macedo KA; Tatarian P; Eugenio KR
    Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
    Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
    Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
    Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
    Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
    Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
    J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
    Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
    Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
    Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?
    Zhao Y; Arya R; Couchman L; Patel JP
    Blood; 2020 Oct; 136(15):1783-1785. PubMed ID: 32488251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.